Pharmetheus https://validator.w3.org/feed/docs/rss2.html Open-source PBPK modeling of artemether for pediatric extrapolations: integrating enzyme ontogeny, CYP2B6 auto-induction and malnutrition Model-integrated evidence: A vision to expand the role of modeling in drug development and regulatory decision-making An item response theory model with bounded integer subcomponents to describe the Mayo Clinic subscores in patients with ulcerative colitis A circular PK/PD/PK model explains the exposure of bulevirtide and bile salts in adult patients with Hepatitis D Usage and regulatory acceptance of PBPK models in paediatric drug applications: a review of EMA and FDA public assessment reports Rock and roll – deliverables driven by standardized data specifications PBPK modeling of subcutaneous absorption for monoclonal antibodies Food effect prediction of a high permeability/low solubility drug formulated as an amorphous solid dispersion (ASD) using an Open Systems Pharmacology (OSP) PBBM approach An open-source PBBM integrating the particle drifting effect to predict human oral absorption of nanoparticle formulations PBPK workflow for predicting clinical DDI risk of OATP1B1/3 inhibitors utilizing the CP-I biomarker: A case study with cyclosporine A Benchmarking a mechanistic immunogenicity framework: aligning sequence-based epitope predictions with clinical observations Model-informed fixed dosing of rozanolixizumab in gMG: PK/PD advantages and comparison with other FcRn blockers Visual predictive checks for real-world data using propensity-score-matching The use of full random effect models (FREM) in model informed precision dosing (MIPD) for a priori dose predictions A mechanism-based parsimonious CAR-T cell population PK model and its validation via extension to a population PK-tumor size dynamics model: case study with axicabtagene ciloleucel and brexucabtagene autoleucel Apparent time dependence and rethinking random effect under single time-to-event models Food effect prediction of high permeability/low solubility, formulated as an amorphous solid dispersion (ASD) using an open systems pharmacology (OSP) PBBM approach News Events Workshop catalog Home Pharmetheus at ESMO 2026 Martina Lundgren Workshop at ACoP 2026: Best use of TTE and RTTE modeling in NONMEM Integrating in silico epitope prediction and mechanistic QSP modeling for benchmarking immunogenicity risk Training workshops Open Systems Pharmacology Community Conference (OSP-CC) Proceedings 2025 Population pharmacokinetic analysis of doxecitine and doxribtimine in patients with thymidine kinase 2 deficiency and in healthy volunteers Population pharmacokinetics and exposure-response analyses of navepegritide in children with achondroplasia The decision-equivalence metric (DEM) method based evaluation of biomarker surrogacy in MASH The visual predictive check and real-world data Model-based approach for a new Prolonged-Release (PR) formulation of ivabradine: PK and PKPD assessment to support bioequivalence Predicting atorvastatin acid pharmacokinetics in a complex enzyme- and transporter-mediated drug–drug interaction network using physiologically based pharmacokinetic modeling Population Pharmacokinetics and Exposure–Response Relationships of Etrolizumab in Patients with Moderately-to-Severely Active Crohn’s Disease Population pharmacokinetic analysis of an octreotide depot (CAM2029) in the treatment of acromegaly Assessing Drug–Drug Interaction and Food Effect for BCS Class 2 Compound BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma Antagonist, Bevurogant) Using a Physiology-Based Pharmacokinetics Modeling (PBPK) Approach with Semi-Mechanistic Absorption Pharmacokinetic characterization and exposure–response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria Pharmetheus at GMP 2026 Symposium Bimekizumab population pharmacokinetic and exposure-response analyses in adults with moderate to severe hidradenitis suppurativa A quantitative systems pharmacology framework of immunogenicity to propose mitigation strategies after subcutaneous administration Population pharmacokinetic and dose–response models of nepadutant, a selective antagonist of the NK₂ receptors, in infants with colic Population pharmacokinetics of survodutide in subjects with overweight or obesity with and without Type 2 Diabetes Mellitus based on Phase I and Phase II data TransCon CNP (Navepegritide): A semi-mechanistic model to describe the prolonged half-life of C-type natriuretic peptide through TransConTM technology Pharmetheus at OSP Community Conference Exploring the relationship between BI 456906 exposure and change in fasting plasma glucose, fasting serum insulin, and glycated hemoglobin (HbA1c) using population PKPD modeling A disease model predicting placebo response and remission status of patients with ulcerative colitis using modified Mayo score Quantitative Relationship Between Tominersen Concentrations in Cerebrospinal Fluid and Biomarker Changes in Huntington’s Disease Patients Use of informative prior distributions from mepolizumab data to support depemokimab PKPD model analysis Target engagement analysis of belimumab in patients with systemic lupus erythematosus (SLE) and primary Sjogren’s syndrome (pSS) Model-Informed Drug Development in Small Populations